Form 4: Guardant Health Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported the acquisition and disposal of company stock and restricted stock units on January 1, 2025.
Summary
- John G. Saia, the Chief Legal Officer of Guardant Health, Inc., filed a Form 4 detailing changes in his beneficial ownership of company securities.
- On January 1, 2025, Saia acquired 974 shares of common stock and 974 restricted stock units through vesting.
- He also acquired 1,667 shares of common stock and 1,667 restricted stock units through vesting.
- Additionally, 1,500 shares were disposed of to cover tax withholding obligations at a price of $30.55 per share.
- Following these transactions, Saia directly owns 34,701 shares of common stock and 11,671 restricted stock units.
Sentiment
Score: 6
Explanation: The document reflects routine insider transactions related to equity compensation. There are no significant positive or negative implications for the company's performance or outlook.
Positives
- The vesting of restricted stock units indicates continued alignment of the executive's interests with the company's performance.
Negatives
- The disposal of 1,500 shares, while for tax obligations, represents a reduction in the executive's direct shareholding.
Risks
- While the transactions are routine, significant changes in insider ownership could be perceived negatively by the market.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders. This filing is typical for executives receiving equity compensation.
Comparison to Industry Standards
- Form 4 filings are a common practice across all publicly traded companies in the US, including biotechnology and healthcare companies like Guardant Health.
- The vesting schedules for restricted stock units, such as the four-year and three-year vesting periods mentioned, are typical for executive compensation packages in the industry.
- The tax withholding process, where shares are sold to cover tax obligations, is also a standard practice in equity compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 2022-11-07 | Date of grant for a restricted stock unit award that vests over four years. |
| 2023-12-13 | Date of grant for a restricted stock unit award that vests over three years. |
| 2023-10-01 | 25% of the shares subject to the November 7, 2022 award vested. |
| 2024-10-01 | 33% of the shares subject to the December 13, 2023 award vested. |
| 2025-01-01 | Date of reported transactions including acquisition of shares and restricted stock units and disposal of shares for tax obligations. |
| 2025-01-03 | Date the Form 4 was signed. |
Keywords
Form 4, Guardant Health, insider trading, stock options, restricted stock units, John G. Saia, beneficial ownership, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.